Market Publishers

+357 96 030922
info@marketpublishers.com

Bleeding Disorders Testing Market By Product (Reagents and Consumables, Instruments) , By Indication (Hemophilia A, Hemophilia B, Von Willebrand Disease, Others) By End User (Hospitals and Clinics, Diagnostic Centers, Others) : Global Opportunity Analysis and Industry Forecast, 2024-2033

https://marketpublishers.com/r/B5A183BB1B04EN.html
Date: November 2024
Pages: 260
Price: US$ 2,655.00 (Single User License)
ID: B5A183BB1B04EN

Abstracts

The bleeding disorders testing market was valued at $90.9 million in 2023, and is projected to reach $192.0 million by 2033, growing at a CAGR of 7.8% from 2024 to 2033.

Bleeding disorders are a group of medical conditions that impair the body’s ability to control blood clotting or coagulation, a process essential to prevent excessive bleeding after an injury. For diagnosing disorders that cause excessive bleeding or bruising, bleeding disorders testing are used to identify and evaluate conditions that affect the blood’s ability to clot. Early diagnosis through testing is essential for effective treatment and management, as it helps prevent potential complications, including joint damage, internal bleeding, and life-threatening hemorrhages.

The growth of the global bleeding disorders testing market alarming increase in prevalence of bleeding disorders and rise in awareness of early and accurate diagnostic testing. As per a 2022 study by Statista, approximately 208,957 individuals worldwide were suffering from hemophilia A and around 17,626 individuals had other platelet disorders. This emphasizes the urgent need for bleeding disorders testing to reduce the risk of these disorders and improve long-term outcomes. In addition, rise in trend of personalized medicine, which involves tailoring treatment plans as per individual's

needs, fosters the market growth. This is attributed to the fact that personalized treatment plans require specific diagnostic testing to identify the precise nature of a bleeding disorder. Furthermore, as healthcare systems in emerging economies improve, access to diagnostic testing for bleeding disorders is increasing, thus expanding the market. Moreover, increase in newborn screening programs to enable early diagnosis and treatment of bleeding disorders acts as a key deterrent factor of the global market. These programs aim to reduce complications from undiagnosed conditions and improve long-term health outcomes. For instance, in 2018, the World Federation of Hemophilia developed a global registry, the WBDR, that allows hemophilia treatment centers to collect clinical data, monitor patient care, and identify gaps in management & treatment. However, high cost associated with genetic and molecular testing for bleeding disorders restrains the market growth. In addition, lack of awareness about bleeding disorders results in underdiagnosis and low demand for testing, which acts as a key deterrent factor of the global market. On the contrary, development of advanced diagnostic tools, including genetic testing and point-of-care diagnostics, has improved the accuracy and speed of bleeding disorder detection, leading to higher adoption rates in healthcare settings. Such developments are expected to offer lucrative opportunities for the expansion of the global market during the forecast period.

The global bleeding disorders testing industry is segmented into product, indication, end user, and region. On the basis of product, the market is bifurcated into reagents & consumables and instruments. Depending on indication, it is divided into hemophilia A, hemophilia B, Von Willebrand disease, and others. By end user, it is segregated into hospitals & clinics, diagnostic centers, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of product, the reagent & consumables is expected to dominate the market from 2024 to 2033.

Depending on indication, the hemophilia A is anticipated to exhibit the highest growth during the forecast period.

By end user, the hospitals & clinics segment is projected to lead the bleeding disorders testing market in the near future.

Region wise, North America held the largest market share in terms of revenue in 2023, and is expected to dominate the market during the forecast period.

+357 96 030922
info@marketpublishers.com

Competition Analysis

Competitive analysis and profiles of the major players in the global bleeding disorders testing market include Siemens Healthineers, Abbott Laboratories, Roche Diagnostics, Bio-Rad Laboratories, Inc., Sysmex Corporation, Thermo Fisher Scientific Inc., Grifols S.A., Danaher Corporation, Medtronic Plc, and Novo Nordisk A/S. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the competitive market.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)

5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.

Free Upcoming Version on the Purchase of Five and Enterprise User License.

16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)

15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)

Free data Pack on the Five and Enterprise User License. (Excel version of the report)

Free Updated report if the report is 6-12 months old or older.

24-hour priority response*

Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Additional company profiles with specific to client's interest

Expanded list for Company Profiles

Historic market data

Key Market Segments

By Product

Reagents and Consumables

Instruments

By Indication

Hemophilia A

Hemophilia B

Von Willebrand Disease

Others

By End User

Hospitals and Clinics

Diagnostic Centers

Others

By Region

+357 96 030922
info@marketpublishers.com

North America

U.S.

Canada

Mexico

Europe

France

Germany

Italy

Spain

UK

Rest of Europe

Asia-Pacific

China

Japan

India

South Korea

Australia

Rest of Asia-Pacific

LAMEA

Brazil

+357 96 030922
info@marketpublishers.com

South Africa

Saudi Arabia

Rest of LAMEA

Key Market Players

Siemens Healthineers

Abbott Laboratories

Roche Diagnostics

Bio-Rad Laboratories, Inc.

Sysmex Corporation

Thermo Fisher Scientific Inc.

Grifols S.A.

Danaher Corporation

Medtronic plc

Novo Nordisk A/S

+357 96 030922
info@marketpublishers.com

Contents

+357 96 030922
info@marketpublishers.com

CHAPTER 8: COMPETITIVE LANDSCAPE

CHAPTER 9: COMPANY PROFILES

+357 96 030922
info@marketpublishers.com

Market Publishers

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Bleeding Disorders Testing Market By Product (Reagents and Consumables, Instruments) , By Indication (Hemophilia A, Hemophilia B, Von Willebrand Disease, Others) By End User (Hospitals and Clinics, Diagnostic Centers, Others) : Global Opportunity Analysis and Industry Forecast, 2024-2033

Product link: https://marketpublishers.com/r/B5A183BB1B04EN.html

Price: US$ 2,655.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/B5A183BB1B04EN.html